Marina Biotech is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). We are building multiple cutting-edge drug discovery and development platforms based on the premise that no single RNAi technology or delivery approach can be broadly applied to the treatment of all human diseases.
To meet the target and indication-specific needs unique to each disease, Marina Biotech provides multiple RNAi therapeutic approaches. We have implemented a multi-faceted, multi-disciplinary and multi-technology approach to discovering novel and proprietary RNAi-based therapeutics that we are confident will lead to clinical success.
We are currently employing two proven RNAi platforms to down-regulate the expression of specific proteins that cause disease:
- TauRNAi which is a combination of our proprietary UsiRNA technology for the construction of small interfering RNA (siRNA) and our novel dialkylated amino acid-based liposome (DiLA2) delivery system
- TransKingdom RNAi™, or tkRNAi, which is an expressed RNA in a bacterial delivery system.
These approaches give us the flexibility to optimize oral, systemic and local delivery of RNAi-based therapies to target a wide range of human diseases based on the unique characteristics of the cells and organs involved in each disease.